340 related articles for article (PubMed ID: 31598150)
1. Glioblastoma Treatment Modalities besides Surgery.
Zhang H; Wang R; Yu Y; Liu J; Luo T; Fan F
J Cancer; 2019; 10(20):4793-4806. PubMed ID: 31598150
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review.
Fabian D; Guillermo Prieto Eibl MDP; Alnahhas I; Sebastian N; Giglio P; Puduvalli V; Gonzalez J; Palmer JD
Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30717372
[TBL] [Abstract][Full Text] [Related]
3. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Zhu P; Zhu JJ
Chin Clin Oncol; 2017 Aug; 6(4):41. PubMed ID: 28841803
[TBL] [Abstract][Full Text] [Related]
4. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
5. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme.
Chin C; Lunking ES; de la Fuente M; Ayad NG
Front Oncol; 2018; 8():521. PubMed ID: 30483476
[TBL] [Abstract][Full Text] [Related]
7. Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies.
Mittal S; Klinger NV; Michelhaugh SK; Barger GR; Pannullo SC; Juhász C
J Neurosurg; 2018 Feb; 128(2):414-421. PubMed ID: 28298023
[TBL] [Abstract][Full Text] [Related]
8. [Survival analysis following the addition of temozolomide to surgery and radiotherapy in patients with glioblastoma multiforme].
Gil-Salú JL; Román P; Benítez E; Maestro E; Pérez-Requena J; López-Escobar M
Neurocirugia (Astur); 2004 Apr; 15(2):144-50. PubMed ID: 15159792
[TBL] [Abstract][Full Text] [Related]
9. Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma.
Matsui JK; Perlow HK; Ritter AR; Upadhyay R; Raval RR; Thomas EM; Beyer SJ; Pillainayagam C; Goranovich J; Ong S; Giglio P; Palmer JD
Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35885067
[TBL] [Abstract][Full Text] [Related]
10. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
11. Management of glioblastoma.
Aoki T; Hashimoto N; Matsutani M
Expert Opin Pharmacother; 2007 Dec; 8(18):3133-46. PubMed ID: 18035958
[TBL] [Abstract][Full Text] [Related]
12. Towards tailored therapy of glioblastoma multiforme.
Rekers NH; Sminia P; Peters GJ
J Chemother; 2011 Aug; 23(4):187-99. PubMed ID: 21803695
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma multiforme: State of the art and future therapeutics.
Wilson TA; Karajannis MA; Harter DH
Surg Neurol Int; 2014; 5():64. PubMed ID: 24991467
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
16. Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.
Ung N; Yang I
J Neurooncol; 2015 Jul; 123(3):473-81. PubMed ID: 26070553
[TBL] [Abstract][Full Text] [Related]
17. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
[TBL] [Abstract][Full Text] [Related]
18. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
20. New molecularly targeted therapies for glioblastoma multiforme.
Polivka J; Polivka J; Rohan V; Topolcan O; Ferda J
Anticancer Res; 2012 Jul; 32(7):2935-46. PubMed ID: 22753758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
